Marielle Dejeneffe
Overview
Explore the profile of Marielle Dejeneffe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tondreau T, Meuleman N, Stamatopoulos B, De Bruyn C, Delforge A, Dejeneffe M, et al.
Cytotherapy
. 2009 Jun;
11(5):559-69.
PMID: 19551542
Background Aims: The transmigratory capacity of bone marrow (BM) mesenchymal stromal cells (MSC) through the endothelial cell barrier into various tissues and their differentiation potential makes them ideal candidates for...
2.
Tondreau T, Dejeneffe M, Meuleman N, Stamatopoulos B, Delforge A, Martiat P, et al.
BMC Genomics
. 2008 Apr;
9:166.
PMID: 18405367
Background: Neuronal tissue has limited potential to self-renew or repair after neurological diseases. Cellular therapies using stem cells are promising approaches for the treatment of neurological diseases. However, the clinical...
3.
Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, et al.
Exp Hematol
. 2007 Aug;
35(10):1527-37.
PMID: 17697742
Objective: Chronic lymphocytic leukemia (CLL) cells develop chemoresistance over time associated with defects in apoptosis pathway. Novel treatment strategies are required to overcome resistance of cells to commonly used agents....
4.
Meuleman N, Tondreau T, Delforge A, Dejeneffe M, Massy M, Libertalis M, et al.
Eur J Haematol
. 2006 Mar;
76(4):309-16.
PMID: 16519702
The expansion of mesenchymal stem cells (MSCs) strongly depends on the culture conditions and requires medium supplemented with 10-20% fetal calf serum (FCS) to generate relevant numbers of cells. However,...
5.
Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M, et al.
Stem Cells
. 2005 Jun;
23(8):1105-12.
PMID: 15955825
In this study, we used a common procedure to assess the potential of mobilized peripheral blood (MPB) and umbilical cord blood (UCB) as sources of mesenchymal stem cells (MSCs) in...
6.
Tondreau T, Lagneaux L, Dejeneffe M, Massy M, Mortier C, Delforge A, et al.
Differentiation
. 2004 Nov;
72(7):319-26.
PMID: 15554943
Bone marrow mesenchymal stem cells (MSC) are multipotent cells. To explain their plasticity, we postulated that undifferentiated MSC may express proteins from other tissues such as neuronal tissues. MSC are...
7.
Lagneaux L, de Meulenaer E, Delforge A, Dejeneffe M, Massy M, Moerman C, et al.
Exp Hematol
. 2002 Nov;
30(11):1293-301.
PMID: 12423682
Objective: We evaluated the cytotoxic effect of ultrasonic irradiation at low energy on the viability of normal and leukemic cells and the potential mechanisms of action inducing this cytotoxicity. Materials...
8.
Lagneaux L, Delforge A, Dejeneffe M, Massy M, Bernier M, Bron D
Leuk Lymphoma
. 2002 Aug;
43(5):1087-95.
PMID: 12148891
We tested the effects of hydroxychloroquine (HCQ), an anti-rheumatic drug, on the viability of chronic lymphocytic leukemia (CLL) cells. HCQ induced a decrease in cell viability in a dose- and...